Company |
Partner |
Amt. |
Details |
Date |
TOTAL: $49.15M (Year to Date: $488.66M) | ||||
AC Immune SA (Lausanne, Switzerland) |
Genentech (member of the Roche Group; Basel, Switzerland) |
ND |
For Genentech's selection of a lead antibody development candidate in their collaboration for anti-tau antibodies for Alzheimer's and other neurodegenerative diseases |
7/14/15 |
Cellectis SA (Paris) |
Les Laboratoires Servier (Paris) |
ND |
For the preclinical development of two next-generation candidates to treat solid tumors |
7/10/15 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Biogen Inc. (Cambridge, Mass.) |
$2.15 |
For advancing the ongoing pivotal phase III study (Cherish) evaluating ISIS-SMNRx in children with spinal muscular atrophy |
7/15/15 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Roche AG (Basel, Switzerland) |
$22 |
For the initiation of the phase I/IIa study of ISIS-HTTRx in patients with Huntington's disease |
7/22/15 |
Macrogenics Inc. (Rockville, Md.) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
$10 |
For initiating dosing in a phase I trial of MGD011 (also known as JNJ-64052781), which incorporates the company's platform for Dual-Affinity Re-Targeting, or DART, to simultaneously target CD19 and CD3 for the potential treatment of B-cell malignancies |
7/29/15 |
Molecular Partners AG (Zurich-Schlieren, Switzerland) |
Allergan plc (Dublin) |
$15 |
For initiating phase III trials with abicipar pegol for the treatment of wet age-related macular degeneration |
7/8/15 |
Morphosys AG (Martinsried, Germany) |
Novartis AG (Basel, Switzerland) |
ND |
For the initiation of a phase I trial of an antibody in the field of blood disorders sourced from Morphosys' Human Combinatorial Antibody Library |
7/24/15 |
Pieris Pharmaceuticals Inc. (Freising, Germany) |
Daiichi Sankyo Co. Ltd. (Tokyo) |
ND |
For the achievement of positive in vivo proof-of-concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates |
7/9/15 |
Spero Therapeutics LLC (Cambridge, Mass.) |
Roche AG (Basel, Switzerland) |
ND |
As part of the companies' ongoing collaboration on Spero's multiple virulence factor regulator (MVFR) inhibitor program of anti-infectives |
7/22/15 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Biogen Inc. (Cambridge, Mass.) |
$2.15 |
For advancing the ongoing pivotal phase III study (Cherish) evaluating ISIS-SMNRx in children with spinal muscular atrophy |
7/15/15 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Roche AG (Basel, Switzerland) |
$22 |
For the initiation of the phase I/IIa study of ISIS-HTTRx in patients with Huntington's disease |
7/22/15 |
Macrogenics Inc. (Rockville, Md.) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.0 |
$10 |
For initiating dosing in a phase I trial of MGD011 (also known as JNJ-64052781), which incorporates the company's platform for Dual-Affinity Re-Targeting, or DART, to simultaneously target CD19 and CD3 for the potential treatment of B-cell malignancies |
7/29/15 |
Molecular Partners AG (Zurich-Schlieren, Switzerland) |
Allergan plc (Dublin) |
$15 |
For initiating phase III trials with abicipar pegol for the treatment of wet age-related macular degeneration |
7/8/15 |
Morphosys AG (Martinsried, Germany) |
Novartis AG (Basel, Switzerland) |
ND |
For the initiation of a phase I trial of an antibody in the field of blood disorders sourced from Morphosys' Human Combinatorial Antibody Library |
7/24/15 |
Pieris Pharmaceuticals Inc. (Freising, Germany) |
Daiichi Sankyo Co. Ltd. (Tokyo) |
ND |
For the achievement of positive in vivo proof-of-concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates |
7/9/15 |
Spero Therapeutics LLC (Cambridge, Mass.) |
Roche AG (Basel, Switzerland) |
ND |
As part of the companies' ongoing collaboration on Spero's multiple virulence factor regulator (MVFR) inhibitor program of anti-infectives |
7/22/15 |
|
Notes Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. This chart includes only biotech companies that develop therapeutics. ND = Not disclosed. | ||||